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Fat distribution is closely linked to metabolic disease risk. Distribution varies with sex, genetic background,
disease state, certain drugs and hormones, development, and aging. Preadipocyte replication and differen-
tiation, developmental gene expression, susceptibility to apoptosis and cellular senescence, vascularity,
inflammatory cell infiltration, and adipokine secretion vary among depots, as do fatty-acid handling and
mechanisms of enlargement with positive-energy and losswith negative-energy balance. How interdepot dif-
ferences in these molecular, cellular, and pathophysiological properties are related is incompletely under-
stood. Whether fat redistribution causes metabolic disease or whether it is a marker of underlying processes
that are primarily responsible is an open question.Introduction
The prevalence of obesity has increased dramatically in recent
years. The clinical description of obesity has largely been based
on measurements, such as body mass index (BMI), that gauge
total body fat. Over the past 50 years, scientists have recognized
that not all adipose tissue is alike (reviewed in Arner, 2005) and
that health risk is associated with the location as well as the
amount of body fat. Different depots are sufficiently distinct
with respect to fatty-acid storage and release as to probably
play unique roles in human physiology. The major anatomical
fat depots include intra-abdominal (omental and mesenteric
depots, also termed visceral fat), lower-body (gluteal fat, subcu-
taneous leg fat, and intramuscular fat), and upper-body subcu-
taneous fat (Figure 1). Within the trunk, Scarpa’s fascia sepa-
rates superficial and deep abdominal subcutaneous fat. Deep
subcutaneous fat accumulation is correlated with visceral fat
accumulation (Kelley et al., 2000). Fat distribution varies remark-
ably between sexes, among individuals and families, with aging
and disease states, and in response to drugs and hormones.
Central obesity is associatedwith increased risk for diabetes, hy-
pertension, atherosclerosis, dyslipidemia, cancers, andmortality
compared to peripheral obesity (reviewed in Shuster et al., 2012).
Even humans of a normal weight with a high ratio of central-to-
peripheral fat have an increased likelihood of being insulin resis-
tant (Kahn et al., 2001).
We begin by reviewing fat-tissue function and its cellular basis.
We examine the role of variations in cellular composition and
function, adipokine secretion, and fatty-acid storage and release
among depots. We conclude by discussing controversies about
whether functional characteristics of different fat depots
contribute to distinct effects on human physiology and whether
intra-abdominal fat is a cause or consequence of systemicmeta-
bolic dysfunction.644 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.Fat-Tissue Function
The principal function of adipose tissue is to store and release fat
in response to energy-balance needs. Adipose tissue also has
immune, endocrine, regenerative, mechanical, and thermal func-
tions (reviewed in Thomou et al., 2010). Both the fuel and nonfuel
functions of adipose tissue vary among depots, with depot size,
and with body-fat distribution. Potentially, when dysregulation of
fatty-acid storage and release occurs in upper-body obesity,
fatty-acid overflow into ‘‘ectopic’’ sites leads to lipotoxicity
(Tchkonia et al., 2006a). In addition to their role as major sources
of cellular fuel, fatty acids can serve as signaling molecules in the
form of diacylglycerols, ceramides, and long-chain acyl-coen-
zymes A. These molecules can exert adverse effects on cell
function, including interference with insulin signaling, when pre-
sent in excess.
Fat is situated under the epidermis and around vital organs,
where it plays immunologically defensive and mechanically pro-
tective roles (Cousin et al., 1999; Duffaut et al., 2009). Once in-
flamed, adipose tissue shifts from storing to releasing fatty acids,
potentially driven in part through local proinflammatory cytokine
release (Faty et al., 2012; Zhang et al., 1996). The proinflamma-
tory response of fat tissue to bacterial antigens such as lipopoly-
saccharide may combine with high local concentrations of fatty
acids during ensuing cytokine-induced lipolysis to mitigate
infection (Chung et al., 2006; Desbois and Smith, 2010; Tchkonia
et al., 2006a; Thomou et al., 2010). Obesity, aging, and lipody-
strophies are associated with sustained fat-tissue immune-
response activation, proinflammatory cytokine release, impaired
insulin responsiveness, reduced incorporation of fatty acid as tri-
glycerides, and increased lipolysis (Tchkonia et al., 2010; Tho-
mou et al., 2010). This contributes to low-grade ‘‘sterile’’ sys-
temic inflammation, metabolic dysregulation, and lipotoxicity,
with different fat depots potentially contributing in distinct ways.
Figure 1. Anatomy of Major Fat Depots
in Rodents and Humans
Several different names for particular fat depots in
rodents (A) and humans (B) are used, as are
different groupings of fat depots for physiological
and clinical studies. The names and anatomies of
the fat depots reviewed here are indicated.
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New fat cells appear throughout life (Spalding et al., 2008;
Tchoukalova et al., 2010). There is controversy and some confu-
sion about nomenclature for the progenitor cells in stromal-
vascular digests of fat tissue that give rise to new fat cells (see
Supplemental Information available online; Cawthorn et al.,
2012). In this review, these cells are collectively termed ‘‘preadi-
pocytes.’’ They account for 15 to 50 percent of cells in fat tissue,
perhaps the largest pool of progenitors in humans, facilitating
regenerative responses to nutrient excess and injury. Preadipo-
cytes tend to be associated with blood vessels and may be
derived from fat-tissue endothelial cells or pericytes (Gupta
et al., 2012; Tang et al., 2008; Tran et al., 2012). They are multi-
potent, appearing to be capable of differentiating into macro-
phages, muscle or bone progenitors, brown fat, and other cell
types (Figure 2A; Charrie`re et al., 2003; Rodriguez et al., 2004;
Schulz et al., 2011; Zuk et al., 2002). Preadipocytes generate adi-
pokines, paracrine factors, hormones, andmetabolic signals in a
manner distinct from fat cells. Several adipokines are secreted in
a fat-depot-dependent fashion (Table 1). Like macrophages,
preadipocytes exhibit robust innate immune responses to bacte-
rial antigens, recruit macrophages and other immune effectors,
and participate in initiating and regulating fat-tissue immune acti-
vation (Gustafson et al., 2009; Lacasa et al., 2007; Thomou et al.,
2010). Preadipocyte gene-expression profiles are closer to those
of macrophages, into which they may be able to convert, than to
those of fat cells (Charrie`re et al., 2003; Prunet-Marcassus et al.,
2006).
Preadipocytes differentiate into fat cells in response to insulin-
like growth factor-1 (IGF-1), lipids, glucocorticoids, and other
signals (Figure 2B; Cristancho and Lazar, 2011). IGF-1, rather
than insulin, is probably the main driver of adipogenesis, given
that insulin receptors are not highly expressed until preadipo-
cytes are partially differentiated (Cawthorn et al., 2012). A
cascade involving CCAAT/enhancer binding proteins (C/EBPs),
peroxisome proliferator-activated receptor g (PPARg), and other
transcription factors orchestrates changes in expression of
around 2,500 genes during adipogenesis (Figure 2C; reviewed
in Tang and Lane, 2012).
At least two preadipocyte subtypes are present in rodent and
human fat (Prunet-Marcassus et al., 2006; Tchkonia et al., 2005).
The first is capable of more extensive replication, differentia-Cell Metabolismtion, and adipogenic transcription-fac-
tor expression and less apoptosis in
response to tumor necrosis factor a
(TNF-a) than the second. Both subtypes
develop in colonies cultured from single
preadipocytes, confirming that both are
within the adipocyte lineage and that
they can interconvert. The adipogene-sis-resistant subtype may sustain the progenitor pool, because
its presence ensures that not all preadipocytes become fat cells
under conditions favoring adipogenesis. The subtypes might
facilitate tissue plasticity, for example, through differentiation
into fat cells with distinct properties or through selection for the
apoptosis-resistant subtype by increased local inflammatory
cytokines (Tchkonia et al., 2005). More investigation is needed
for determining the functional relevance of preadipocyte sub-
types and whether they account for the two fat cell populations
that differ in size observed in rodents and humans (Blu¨her
et al., 2004; Julien et al., 1989).
Preadipocytes can undergo cellular senescence, particularly
with aging and obesity (Minamino et al., 2009; Tchkonia et al.,
2010). Senescent cells release proinflammatory cytokines, che-
mokines, and extracellular matrix proteases, termed the senes-
cence-associated secretory phenotype, or SASP (reviewed in
Freund et al., 2010). Preadipocytes from old rats are proinflam-
matory and express SASP components (Cartwright et al.,
2010; Tchkonia et al., 2010). Interleukin-6 (IL-6), plasminogen-
activator inhibitor 1 (PAI-1), and other SASP components are
much more highly expressed in senescent cells isolated by fluo-
rescence-activated cell sorting from the stromal-vascular frac-
tion of mouse adipose tissue than in neighboring nonsenescent
cells (Baker et al., 2011). When senescent cells are eliminated
from older mice, age-related fat-tissue loss is delayed or pre-
vented, confirming the relevance of senescent cells to age-
related fat-tissue dysfunction (Baker et al., 2011).
Regional Differences in Preadipocyte Characteristics
Replication
During weight gain, different fat depots enlarge via hyperplasia,
hypertrophy, or both (Tchoukalova et al., 2010). New adipocytes
can be generated more rapidly in some depots than others
(Figure 3). Modest femoral subcutaneous fat tissue enlargement
in response to overfeeding in young adults is due to increases in
cell number, not size. The opposite is true for moderate amounts
of abdominal subcutaneous fat gain. At least in rats, visceral fat
mass changes principally through adjustments in adipocyte size,
rather than number (DiGirolamo et al., 1998). Regional differ-
ences in preadipocyte replication, differentiation, subtype abun-
dance, susceptibility to apoptosis or senescence, and gene
expression may contribute to regional variation in fat-tissue17, May 7, 2013 ª2013 Elsevier Inc. 645
Figure 2. Regional Variation in Fat-Tissue Cell Dynamics
(A) Regional variation in fat-tissue cell dynamics. Preadipocytes arise
from resident multipotent mesenchymal progenitor cells, which are
generally associated with blood vessels and may be related to endothelial
cells or pericytes, and can possibly become committed to brown fat,
myocyte, osteocyte, chondrocyte, or macrophage lineages (see Supple-
mental Information for a note regarding nomenclature). Circulating pro-
genitors may contribute, especially to visceral fat development (Crossno
et al., 2006).
(B) Committed preadipocytes can replicate, differentiate into adipocytes, or
possibly revert into multipotent progenitors again. At least two interconvertible
preadipocyte subtypes exist; one is more capable of replication, differentia-
tion, and resistance of apoptosis than the other. Preadipocytes can be induced
to differentiate by IGF-1 and other stimuli. Differentiated fat cells vary lipid
content through esterifying exogenous fatty acids to glycerol, de novo lipo-
genesis, or fatty-acid release through lipolysis.
646 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.
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requires more research to test. It is noteworthy that genome-
wide association studies suggest that body-fat distribution, as
measured by waist-hip ratio, is associated with variations in
genes involved in pattern formation during embryonic develop-
ment, angiogenesis, preadipocyte signaling, and adipocyte
development, all pointing toward heritable differences in adipo-
cyte characteristics (Heid et al., 2010). Other gene variations
associated with waist-hip ratio include those in the insulin
signaling, lipase-activity, lipid-biosynthesis, and intracellular-
calcium signaling pathways. These relationships are indepen-
dent of BMI and differ between women and men.
Differences in cell-dynamic properties of preadipocytes are
partly cell autonomous. Strains derived from single human or
rodent preadipocytes from different depots and cultured under
identical conditions retain distinct capacities for adipogenesis
and replication, susceptibilities to apoptosis, and developmental
gene-expression patterns after many generations, despite orig-
inating from the same individuals (Adams et al., 1997; Gesta
et al., 2006; Kirkland et al., 1990, 1996; Tchkonia et al., 2002,
2006b, 2007; Wang et al., 1989). For example, rat perirenal pre-
adipocytes are capable of more extensive replication than
epididymal preadipocytes (Kirkland et al., 1990; Wang et al.,
1989). These differences remain evident for at least 3 weeks in
colonies arising from single perirenal or epididymal preadipo-
cytes (Kirkland et al., 1990). The greater replicative potential of
rat perirenal than epididymal preadipocytes is reflected in bigger
increases in perirenal fat cell numbers during development in vivo
(Wang et al., 1989). In humans, colonies derived from individual
abdominal subcutaneous preadipocytes are capable of more
extensive replication on average than omental clones are, with
mesenteric preadipocytes being intermediate (Tchkonia et al.,
2006b, 2005; Van Harmelen et al., 2004). Abundance of the
more rapidly replicating preadipocyte subtype is greater in sub-
cutaneous than omental preadipocyte populations (Tchkonia
et al., 2005). These regional differences in subtype abundance
persisted even after subcloning. Consistent with the greater
replicative potential of subcutaneous than omental preadipo-
cytes, telomeres are shorter in subcutaneous than in omental
cells (Tchkonia et al., 2006b). Stable expression of human telo-
mere reverse transcriptase (hTERT) in single abdominal subcu-
taneous and omental human preadipocytes (in order to increase
survival in culture) showed that, after 35 population doublings,
the rate of subcutaneous clonal replication remained 2.5-fold
higher than that of omental replication (Tchkonia et al., 2006b).(C) Key transcription factors involved in adipogenesis. IGF-1 and other signals
combine to induce adipogenesis, with early increases in cyclic AMP (cAMP)-
and protein kinase A-mediated phosphorylation and activation of CREB, which
along with GSK3b contributes to activation of C/EBPb. Activated C/EBPb
forms homodimers or heterodimers with glucocorticoid-induced C/EBPd that
enhance PPARg expression and activity. Upon binding to a lipid ligand, as well
as to RXRa and its retinoid ligands, PPARg transactivates C/EBPa, the other
major adipogenic transcription factor. PPARg and C/EBPa cooperate to
maintain their own expression, activate SREBP1c (ADD1 in mice), and,
together with SREBP1c, transactivate around 2,500 downstream differentia-
tion-dependent genes. This leads to the acquisition of capacities for adipo-
genesis, lipid storage, insulin responsiveness, and lipolysis; increased secre-
tion of some adipokines (e.g., leptin) and decreased secretion of others (e.g.,
PAI-1); and changes in extracellular matrix component production, micro-
RNAs, histones, and chromatin structure (reviewed in Cristancho and Lazar,
2011; Tang and Lane, 2012).
Table 1. Adipokines Reported to Exhibit Fat-Depot-Specific Expression
Adipokine or
Secreted Factor Source Cells Depot References
Leptin* fat cells subcutaneous > omental (Wiest et al., 2010)
Adiponectin*
HMW
fat cells omental > subcutaneous (Kovacova et al., 2012)
PAI-1 preadipocytes possibly, omental >
subcutaneous
(Xu et al., 2012)
IL-6* preadipocytes, macrophages,
activated endothelial cells, large
fat cells
visceral > subcutaneous (Fontana et al., 2007)
TNF-a* preadipocytes, macrophages,
adipocytes
mesenteric >
omental = subcutaneous
(Cartier et al., 2008; Xu et al., 2012)
MCP-1* preadipocytes, macrophages visceral > subcutaneous (Madani et al., 2009; Miller et al., 2011)
Angiotensinogen fat tissue omental > subcutaneous (Dusserre et al., 2000; van Harmelen et al.,
2000)
RANTES* stromal vascular fraction,
fat cells
gastric fat pad >
omental = subcutaneous
(Madani et al., 2009)
CSF-1 endothelial cells, fibroblasts visceral > subcutaneous (Harman-Boehm et al., 2007)
Omentin stromal vascular cells omental > subcutaneous (Yang et al., 2006)
RBP4 preadipocytes, adipocytes visceral < subcutaneous (Kos et al., 2011)
Chimerin unknown visceral < subcutaneous (Alfadda et al., 2012)
Vaspin fat cells visceral > subcutaneous (Hida et al., 2005; Klo¨ting et al., 2006)
Many adipokines are secreted by adipose tissue. Those that reportedly exhibit regional variation in expression or secretion are included. The cell types
in which they are expressed are indicated. Secretion of several of these adipokines (marked by *) has been verified in studies of arteriovenous con-
centration gradients across adipose depots. Expression or secretion of several of these adipokines is affected by body mass index, fat cell size, or
gender in addition to the adipose depot. The following abbreviations were used: HMW, high molecular weight isoform; PAI-1, plasminogen-activated
inhibitor 1; IL-6, interleukin-6; TNF-a, tumor necrosis factor a; MCP-1, monocyte chemoattractant protein 1; RANTES, regulated on activation, normal
T cell expressed and secreted; CSF-1, colony-stimulating factor 1; and RBP4, retinol binding protein 4.
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are heritable over many cell generations, do not depend on the
presence of other cell types, and are independent of telomerase
activity. It should be noted that individual preadipocytes isolated
from, for example, subcutaneous fat sometimes behave more
like cells characteristic of omental fat, just as some individual
cells from old subjects behave like typical cells from the young
(Kirkland et al., 1990; Tchkonia et al., 2002, 2006b). Characteris-
tics at the cell-population level are determined by the aggregate
behavior of individual clones.
Adipogenesis
Expansion in times of sustained nutrient excess is most effec-
tively achieved through increases in fat cell number, a mecha-
nism especially prominent during fat-tissue expansion in human
femoral subcutaneous depots (Tchoukalova et al., 2010). Human
preadipocyte capacity for adipogenesis appears to vary among
depots in most studies (Adams et al., 1997; Digby et al., 2000;
Hauner et al., 1988; Macotela et al., 2012; Montague et al.,
1998; Niesler et al., 1998; Tchkonia et al., 2002, 2006b), but
not all (Shahparaki et al., 2002; Van Harmelen et al., 2004). Dis-
crepancies might be due to variability among subjects, the point
at which differentiation was assessed, or culture conditions.
Where differences were found, abdominal subcutaneous preadi-
pocytes had a greater capacity for adipogenesis than omental
cells. As with replication, regional differences in adipogenesis
are evident in colonies derived from individual preadipocytes
(Tchkonia et al., 2002), as well as strains made from single sub-cutaneous, mesenteric, and omental hTERT-expressing preadi-
pocytes after 40 population doublings (Tchkonia et al., 2006b). If
left long enough in differentiation-promoting medium, omental
preadipocytes eventually catch up to subcutaneous cells,
obscuring regional differences evident earlier during differentia-
tion (Tchkonia et al., 2002). Abdominal subcutaneous human
preadipocytes tend to differentiate to a greater extent in
response to thiazolidinediones (TZDs) than omental preadipo-
cytes do (Adams et al., 1997; Digby et al., 2000; Hauner et al.,
1988; Montague et al., 1998; Tchkonia et al., 2002). Consistent
with this, administering TZDs promotes more subcutaneous
than visceral fat accumulation (Mori et al., 1999).
PPARg and C/EBPa expression is higher in human abdominal
subcutaneous than in omental differentiating preadipocytes
(Tchkonia et al., 2002, 2006b, 2007). Within clones, C/EBPa is
increased in those cells that acquire lipid inclusions, irrespective
of depot origin, suggesting that regional variation in adipogene-
sis depends on adipogenic transcription-factor expression and
upstreammechanisms (Tchkonia et al., 2002). In rats, interdepot
differences in cultured preadipocyte-differentiation-dependent
gene expression are reflected in patterns of fat-tissue expression
of the same genes (Kirkland et al., 1996). Despite exposure to
hormonal manipulations in vivo, such as estrogen treatment, hy-
pophysectomy, or castration, preadipocytes cultured from
various depots of rats retain differences in adipogenesis, consis-
tent with these differences being cell autonomous (Kirkland
et al., 1992; Lacasa et al., 1997).Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc. 647
Figure 3. Mechanisms of Fat-Tissue
Growth during the Progression of Obesity
Vary among Depots
Some regions of human subcutaneous fat, which
is specialized to provide long-term nutrient stor-
age, grow through increases in fat cell number,
such as femoral fat (A), and others grow through
increases in fat cell size, such as abdominal sub-
cutaneous fat (B). Intraperitoneal fat—the omental
depot, for example (C)—generally enlarges
through increases in fat cell size rather than
number, consistent with its role in storing and
releasing nutrients rapidly and its limited space for
growth. These interdepot differences are related
to higher potentials of subcutaneous than visceral
preadipocytes for replication and adipogenesis.
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Apoptotic fat cells are more abundant in human omental than
abdominal subcutaneous fat (Niesler et al., 1998). Omental
preadipocytes are more susceptible to apoptosis induced by
serum deprivation or TNF-a (Niesler et al., 1998; Tchkonia
et al., 2002; Tchkonia et al., 2006b). Differential susceptibility
to TNF-a-induced apoptosis is retained in hTERT-expressing
omental and subcutaneous strains. Like replication and adipo-
genesis, mechanisms underlying regional variation in apoptosis
appear to be partly cell autonomous.
Both senescent endothelial cells and preadipocytes accumu-
late in adipose tissue with obesity in a depot-dependent manner
(Minamino et al., 2009; Tchkonia et al., 2009, 2010; Villaret et al.,
2010). Although visceral preadipocytes are more proinflamma-
tory than intraperitoneal cells, the trajectory of age-related
increases in SASP components is greater in extra- than intraper-
itoneal preadipocytes, consistent with the earlier age-related
loss of subcutaneous fat compared to intra-abdominal fat (Cart-
wright et al., 2010). Additionally, although macrophage infiltra-
tion is more extensive in visceral than in subcutaneous fat, the
trajectory of the increase in subcutaneous macrophages with
aging is greater in subcutaneous than in visceral fat (Einstein
et al., 2010), paralleling depot-dependent changes in SASP
macrophage chemokines with aging (Cartwright et al., 2010). In-
flammatory cytokines, including TNF-a, that result from the
SASP andmacrophage infiltration are profoundly antiadipogenic
(Zhang et al., 1996). Thus, cellular senescence may contribute to
regional variation in age- and obesity-related increases in fat-tis-
sue inflammation, glucose intolerance, loss of capacity to store
fat in subcutaneous depots, and lipotoxicity (Tchkonia et al.,
2010).
Inherent Differences
IGF-1 is an important driver of adipogenesis (Cawthorn et al.,
2012; Cristancho and Lazar, 2011). Consistent with the greater
capacity for differentiation of subcutaneous than omental648 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.preadipocytes, AKT phosphorylation in
response to IGF-1 is higher in subcutane-
ous cells, despite similar tyrosine phos-
phorylation of IGF-1 receptors (Cleve-
land-Donovan et al., 2010). Serine
phosphorylation of IRS-1, which impedes
the capacity of IRS-1 to transduce insulin
and IGF-1 signaling, is more extensive inomental than subcutaneous preadipocytes, potentially contrib-
uting to the insulin resistance and reduced adipogenic potential
of omental fat.
Genome-wide expression profiles of primary preadipocytes
cultured in parallel from different depots of mice and humans
are highly distinct (Gesta et al., 2006; Tchkonia et al., 2007).
Expression of >500 genes varies significantly among human
abdominal subcutaneous, omental, and mesenteric preadipo-
cytes and fat tissue. Around 25% of transcripts whose expres-
sion varies among depots in both humans and rodents are devel-
opmental regulators, the gene category that differs most (Gesta
et al., 2011, 2006; Karastergiou et al., 2013; Tchkonia et al.,
2007). Prominent among these is the homeobox (HOX) super-
family, which consists of master regulators of developmental
processes controlling the diversification of segments along the
anteroposterior axis of animals. Particular HOX gene combina-
tions, the HOX code, are expressed in adult cells based on their
embryonic origin. Other genes that regulate important develop-
mental pathways also vary, including secreted frizzled-related
protein 2 (SFRP2), pregnancy-associated plasma protein A-1
(PAPP-A1), transcription factor T-box 15 (TBX15), and engrailed
1 (En-1) (Gesta et al., 2006; Tchkonia et al., 2007). Depot-specific
developmental gene-expression signatures persist for 40 popu-
lation doublings in hTERT clones and remain evident in fat cells.
The mesodermal developmental regulator, Tbx15, is expressed
at a >250-fold higher level in rodent subcutaneous cells than in
epididymal cells and affects adipogenesis when overexpressed
(Gesta et al., 2011). There is emerging evidence that genes
important for adipogenesis, including C/EBPa, are regulated by
HOX epigenetic networks (Huang et al., 2012). Whether develop-
mental regulators directly cause regional differences in preadipo-
cyte and fat-depot characteristics is being actively investigated.
Most developmental genes are subject to epigenetic regula-
tion via DNA cytosine methylation and histone lysine methyl-
ation. Cytosine methylation is associated with transcriptional
Cell Metabolism
Reviewrepression through many cell divisions, whereas histone methyl-
ation can result in either inherent activation or repression of tran-
scription (reviewed in Bernstein et al., 2007). The HOX code is
regulated by cellular memory mechanisms involving histone
H3 lysine di- and trimethylation patterns that span large areas.
Other developmental genes that differ among depots, such as
EN-1 and SHOX2, are controlled by DNA cytosine methylation
(Schmidt et al., 2010), whereas SFRP2 is subject to H3 lysine-4
trimethylation for transcriptional activation (Sharma et al.,
2010). Epigenetic mechanisms, including DNA methylation or
histone modifications, appear to be subject to metabolic control
(for example, maternal undernutrition in rodents) (Raychaudhuri
et al., 2008). HOXA5, TBX15, and EN1 change in response to
systemic metabolic challenges, including obesity, in humans
(Gesta et al., 2006). A set of HOX genes (HOXA5, HOXA9, and
EMX2) are induced in response to extreme weight loss after bar-
iatric surgery (Dankel et al., 2010), in tandem with downregula-
tion of inflammatory genes. Whether regional differences in
developmental gene expression are caused by metabolically
regulated epigenetic mechanisms needs to be determined.
Regional differences in preadipocyte cell-dynamic properties
and gene expression could contribute to variation in function
among depots. Consistent with this, interdepot differences in
adipogenesis predict which depots enlarge during development
in rats (Wang et al., 1989). Differences in PPARg and C/EBPa
expression appear to predict interdepot variation in the extent
of new-adipocyte accumulation that is a result of increased
caloric intake in humans (Tchoukalova et al., 2010). Furthermore,
fat tissue transplanted into different depots exerts an impact on
systemic metabolism characteristic of its anatomic origin (Tran
et al., 2008). Additional work is needed for establishing how
inherent properties of fat progenitors affect systemic metabolic
function and, particularly, whether this represents an opportunity
for developing new therapeutic interventions.
Regional Variation in Adipokines
Different fat depots have distinct glycoprotein, adipokine, and
paracrine factor secretion profiles and capacities to activate or
respond to hormones (Table 1). Changes in preadipocyte inflam-
matory cytokine and chemokine production due to obesity and
aging are, in many cases, fat depot dependent (Cartwright
et al., 2010; Tchkonia et al., 2010; Thomou et al., 2010; Xu
et al., 2012). Given that preadipocyte adipokine and paracrine
factor profiles differ from those of fat cells (Table 1; reviewed in
Thomou et al., 2010), regional variation in preadipocyte numbers
relative to differentiated fat cell numbers probably also adds to
interdepot differences in secretory profiles. Furthermore, macro-
phage abundance varies up to 7-fold among depots (Zhang
et al., 2009), which probably contributes to regional variation in
cytokine secretion. Macrophage infiltration is associated with in-
sulin resistance, metabolic syndrome, and morbidity (Cancello
et al., 2006; Harman-Boehm et al., 2007).Macrophage infiltration
into omental fat, but not subcutaneous fat, is associated with
obesity comorbidity and severity of steatosis (Cancello et al.,
2006). Because macrophage characteristics vary among organs
(Murray and Wynn, 2011), fat-tissue macrophages could differ
from other tissue-specific macrophage subtypes and might
even vary among depots. T lymphocyte subsets, mast cells,
and humoral immune-response elements are involved in thefat-tissue inflammation associated with obesity (Liu et al., 2009;
Nishimura et al., 2009). Whether these immune elements or other
types of cells vary among fat depots needs further investigation.
Preadipocytes have toll-like receptors for bacterial antigens
and proinflammatory cytokines (Vitseva et al., 2008), as well as
functional receptors for TNF-a and neuropeptides, such as
substance P (Karagiannides et al., 2006) and neurotensin
(Koon et al., 2009). Substance P and neurotensin induce expres-
sion of proinflammatory cytokines, including IL-6 and I6 8 in pre-
adipocytes, as well as activating NF-kB, at least in mesenteric
preadipocytes. Regional differences in abundance of TNF-a
receptor 1 have been found (Xu et al., 2012). More information
about regional variation in other cytokine receptors and in neuro-
peptide and proinflammatory signaling pathways is needed.
Brown Fat and Regional Differences in Fat-Tissue
Function
Brown adipose tissue generates energy from triglycerides (Seale
et al., 2009). Abundance of brown fat, which is concentrated in
the neck and upper chest of human adults, is inversely correlated
with BMI (Cypess et al., 2009). Brown-fat progenitors may be
related to white-fat preadipocytes, muscle cells, and vascular
endothelial-like cells (Figure 2A; Gupta et al., 2012; Tran et al.,
2012). Preadipocytes in white fat and muscle can become
committed to the brown-fat lineage through induction involving
bone morphogenetic protein 7 (BMP-7) (Schulz et al., 2011).
Human abdominal subcutaneous white-fat preadipocytes have
greater brown-adipocyte lineage commitment potential
following BMP-7 induction than preadipocytes isolated from
mesenteric or omental white depots. Whether brown or ‘‘beige’’
fat cells within different depots have distinct properties needs to
be investigated.
Fat Distribution, Adipose-Tissue Blood Flow,
and Metabolic Dysfunction
Postabsorptive adipose-tissue blood flow is relatively low
compared to other tissues, ranging from 1.5 to 10.0 ml 3 100
g1 3 min1 depending upon the population studied and the
method used to make the measurement (Funada et al., 2010;
Romanski et al., 2000; Virtanen et al., 2002). Both abdominal
and femoral adipose-tissue blood flow increase remarkably
following meal ingestion (Romanski et al., 2000) and in response
to adrenergic stimulation (Ardilouze et al., 2012). Adipose blood
flow is slightly greater in visceral fat than subcutaneous fat (Vir-
tanen et al., 2002). There is some evidence that women may
have more increased femoral adipose-tissue blood flow in the
postprandial period than men do (Romanski et al., 2000).
Obesity, insulin resistance, and endothelial dysfunction are
associated with reduced fasting and meal-stimulated adipose-
tissue blood flow (Funada et al., 2010), which may not be entirely
harmful. Lean adults can increase subcutaneous adipose blood
flow by more than 5-fold following meal ingestion; in someone
with 15 kg of fat, this would result in an increase in adipose blood
flow of over 1 l/min. If a similar proportionate increase in blood
flow were to occur in someone with 50 kg of adipose tissue, car-
diac output would need to almost double in order to maintain
perfusion of other organs. The extent to which adipose-tissue
blood flow is rate limiting with regards to nutrient delivery is not
clear in most conditions.Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc. 649
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Storage
Functional properties differ among the major human fat regions:
intra-abdominal, lower-body, and upper-body subcutaneous fat
(Figure 1). Storage of dietary fatty acids is generally more
efficient in upper-body than in lower-body subcutaneous fat in
normal-weight volunteers who consume appropriately cali-
brated meals (Romanski et al., 2000). Likewise, dietary fat is
stored more efficiently in visceral than in upper- or lower-body
subcutaneous fat (Jensen et al., 2003). Together, subcutaneous
and visceral fat store 50% of dietary fat in sedentary adults,
and the remainder is oxidized within the first 24 hr following
meal ingestion (Jensen et al., 2003; Romanski et al., 2000). In
obesity, regional differences in dietary fat storage are more pro-
found (Santosa et al., 2008; Votruba et al., 2007). Women with
increased leg fat store more dietary fat in this depot. This does
not occur in visceral fat. Furthermore, the pattern of dietary fat
storage relative to fat mass differs considerably between up-
per-body subcutaneous, visceral, and leg fat. Obese men store
less dietary fat in subcutaneous depots than obese women do,
especially lower-body-obese women. The cellular andmolecular
basis for these differences is an open area for investigation.
Free Fatty Acids
Adipose tissue can take up very low density lipoprotein triglycer-
ide (VLDL-TG) and free fatty acids (FFA) directly (Koutsari et al.,
2011, 2012). Direct storage of systemic FFA into adipose tissue
in the postabsorptive state is remarkably different between men
and women and among depots. Women store a substantially
greater portion of systemic FFA in lower-body fat than men do.
Surprisingly, patterns of regional FFA release largely mirror
meal fatty acid, but VLDL-TG fatty acid and direct FFA storage
do not.
Regional Differences in Adipose-Tissue FFA Release
Much of the basic information regarding regional differences in
adipocyte lipolysis was gained using sophisticated in vitro
models (Arner, 2005). These results prompted a series of
whole-body, in vivo studies designed to quantify how these
in vitro differences translated into human physiology. We found
that overnight postabsorptive FFA release per kg of fat is greater
from upper-body than lower-body subcutaneous adipose tissue
in bothmen andwomen (Jensen, 1995). Upper-body subcutane-
ous adipose tissue FFA release accounts for the majority (>60%)
of systemic FFA under basal (Nielsen et al., 2004) and insulin-
suppressed conditions (Guo et al., 1999; Meek et al., 1999).
Lipolysis is markedly accelerated by exercise in both upper-
and lower-body subcutaneous fat (Burguera et al., 2000). Leg
adipose-tissue lipolysis contributes 15%–20% of basal, sys-
temic FFA release in lean adults (Jensen, 1995; Meek et al.,
1999) and 28% in obese adults (Guo et al., 1999; Nielsen
et al., 2004). With hyperinsulinemia (Meek et al., 1999) and
meal ingestion (Guo et al., 1999; Jensen, 1995), leg FFA release
is more readily suppressed than release from upper-body sub-
cutaneous fat. Hepatic vein FFA, a surrogate measure of visceral
adipose lipolysis, appears resistant to insulin’s antilipolytic
effects (Jensen, 1995; Meek et al., 1999). Only 6%–17% of sys-
temic FFA comes from the splanchnic bed under overnight post-
absorptive conditions, but up to 40% during hyperinsulinemia
(Jensen, 1995; Meek et al., 1999). This indicates either that
visceral fat is very resistant to insulin’s antilipolytic effects650 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.compared to subcutaneous fat or that spillover of fatty acids
from hydrolysis of triglyceride-rich lipoproteins is a special issue
in the splanchnic bed (Nelson et al., 2007). In either case, the liver
is probably exposed to higher FFA concentrations than the
periphery during hyperinsulinemia, and this portal-systemic dif-
ference may be exaggerated in upper-body/visceral obesity
(Ali et al., 2011).
Fat-Tissue Lipolysis
The most consistent finding regarding fat-tissue lipolysis is that
much greater FFA release occurs during hyperinsulinemia in up-
per-body/visceral obesity compared with the nonobese or
lower-body-obese state (Guo et al., 1999). Interestingly, individ-
ually cultured omental differentiated preadipocytes have greater
FFA flux than subcutaneous clones do (Caserta et al., 2001),
suggesting that a partially cell-autonomous mechanism could
contribute. Excess postprandial FFA release results in elevated
FFA concentrations (3-fold greater in upper- than lower-body
obesity [Guo et al., 1999]). Because leg adipose tissue lipolysis
is so sensitive to insulin (Meek et al., 1999) andmeal suppression
(Guo et al., 1999; Jensen, 1995), it does not contribute to the
elevated postprandial FFA in obesity. Higher postprandial FFA
concentrations in upper- than in lower-body obesity are almost
entirely accounted for by excess FFA release from upper-body
subcutaneous fat (Guo et al., 1999). This implies that adipocytes
in upper-body obesity are resistant to the antilipolytic effects of
insulin. The explanation for this resistance is unclear. This may
be related to enlarged abdominal or visceral adipocytes in
upper-body obesity being inherently resistant to insulin, with
large adipocytes having greater rates of lipolysis than small ad-
ipocytes, even when they are harvested from the same depot
(Laurencikiene et al., 2011). In adults with severe obesity, large
omental adipocytes are more predictive of metabolic abnormal-
ities than are large abdominal subcutaneous adipocytes (Hoff-
stedt et al., 2010). Lower-body obesity, which is much more
often associated with greater insulin sensitivity with regards to
glucosemetabolism, is also associated with greater adipose-tis-
sue insulin sensitivity with regards to suppression of lipolysis
(Guo et al., 1999). Given the known adverse effects of elevated
FFA on insulin action (Roden et al., 1996), it is possible that the
greater adipose-tissue insulin sensitivity in lower-body obesity
allows greater muscle and hepatic insulin sensitivity. Certainly
weight loss through diet and exercise, which reduces fat cell
size, also improves insulin regulation of lipolysis (Shadid and
Jensen, 2006), whereas liposuction (no decrease in fat cell
size) does not (Klein et al., 2004).
A Special Role for Leg Fat?
The role of leg fat in metabolic function is of growing interest. In
addition to the well-known epidemiological association between
lower-body fat distribution and improved metabolic health, leg
fat appears to serve an important role in disposing of excess di-
etary fat in women (Votruba and Jensen, 2006). Because adipose
tissue lipolysis in leg fat is normally exquisitely sensitive to insulin
(Meek et al., 1999), this makes lower-body depots an ideal place
to store fat when it is ingested in excess of short-term energy
needs. More recently, it has been suggested that leg fat may
even contribute to metabolic health via production of the pur-
ported lipokine, palmitoleic acid (Pinnick et al., 2012).
In summary, excess visceral fat is associated with but is not
the predominant source of excess FFA in humans. Dysregulated
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of visceral obesity and probably contributes to lipotoxicity.
Greater amounts of leg fat signal a lesser metabolic risk and a
more normal fatty-acid profile, although whether leg fat plays a
protective role or (opposite of visceral fat) signals generally
normal function of subcutaneous fat remains to be determined.
The relations between these functional differences and regional
variations in cellular composition, preadipocyte properties, and
cytokine release are poorly understood. Potential local modula-
tors of adipose function with regards to fat storage and release
include abnormal perfusion, accumulation of inflammatory cells,
or paracrine or autocrine effects of adipocytes themselves.
Mesenteric Fat: An Underappreciated Role?
Mesenteric fat may make an important contribution to metabolic
dysfunction, acting in a manner distinct from omental fat (Cata-
lano et al., 2010; Liu et al., 2006). Mesenteric fat is the first depot
to encounter lipids as they travel within chylomicrons from the
gut through lymphatics to join the circulation at the thoracic
duct and vena cava, bypassing the liver. These lipids, especially
saturated fatty acids, might trigger signaling events and innate
immune responses in the various mesenteric fat cell types. In
obese women, lipid synthesis and lipolysis differ between
omental and mesenteric fat (Edens et al., 1993; Fried et al.,
1993). Glucocorticoid deficiency in hydroxysteroid dehydroge-
nase 1 (HSD-1) knockout (KO) mice protects against visceral
obesity by reducing inflammation and preserving b-oxidation in
mesenteric fat, but not in other depots (Wamil et al., 2011). The
mesentery contains autonomic nervous fibers that connect the
spinal ganglia to the gut, potentially linking the nervous system
and mesenteric fat. Substance P, a product of sensory neurons,
has profound proinflammatory and mitogenic effects on mesen-
teric preadipocytes, potentially contributing to the development
of creeping fat in inflammatory bowel disease (IBD; Gross et al.,
2009; Karagiannides et al., 2006). In patients with IBD, mesen-
teric fat lineage cells themselves, as opposed to macrophages
or endothelial cells, are the major source of TNF-a, whereas little
TNF-a was observed in either the subcutaneous fat of these
patients or the mesenteric or subcutaneous fat of healthy con-
trols (Fink et al., 2012). Mesenteric substance P has recently
been implicated in the genesis of insulin resistance (Karagian-
nides et al., 2011a, 2011b).
The cellular and gene-expression properties of humanmesen-
teric fat are cell-autonomously distinct from omental fat (Tchko-
nia et al., 2002, 2006b, 2007). However, both depots contribute
to intra-abdominal fat asmeasured radiographically in clinical tri-
als, raising the possibility that distribution of visceral fat between
the mesenteric and omental depots may have as-yet-unex-
plained clinical implications. There is emerging evidence indi-
cating that mesenteric fat is an independent determinant of
metabolic syndrome and correlates with thickness of the intima
and media of the carotid arteries in humans (Liu et al., 2006). In
support of the speculation that mesenteric fat makes a contribu-
tion to metabolic function, mice with genetically increased life-
span (Ames, Snell, growth hormone receptor KO, and
PAPP-A KO) have substantially reduced mesenteric fat, yet
retain perigonadal fat (J.L.K. and T. Tchkonia, unpublished
data; rodents have very little omental fat—rodent perigonadal
fat is roughly equivalent in function to omental fat in humans).The improved insulin responsiveness that results from calorically
restricting obese rats is associated with reductions inmesenteric
fat, but not other fat depots (Catalano et al., 2010). A closer link
between mesenteric fat and metabolic syndrome than between
omental fat and metabolic syndrome could explain why
removing the omentum appears to have little effect on glucose
tolerance in humans (see the section ‘‘Intra-Abdominal Fat:
Cause or Indicator?’’ below). The effects of targeting mesenteric
fat on glucose responsiveness remain to be investigated.
Metabolically Protective Role of Subcutaneous Fat
Certain subcutaneous fat regions appear to be metabolically,
immunologically, and mechanically protective. Subcutaneous
fat, which can expand outward without the anatomic constraints
that limit visceral fat growth, is specialized to provide long-term
fuel storage, acting as a sink to sequester potentially lipotoxic
fatty acids (Kirkland et al., 2003; Tchkonia et al., 2006a; Thomou
et al., 2010). Consistent with its role in energy storage, subcu-
taneous fat is the major source of leptin, which signals the state
of lipid stores to the brain (Table 1). Dysfunctional subcutaneous
fat is associated with visceral fat enlargement, systemic inflam-
mation, and lipotoxicity (Tchkonia et al., 2006a). Interestingly,
subcutaneous fat abundance increases when visceral fat is
removed from experimental animals (Mauer et al., 2001). When
subcutaneous fat is removed, visceral fat mass, insulin resis-
tance, circulating insulin, and TNF-a increase. This may
contribute to the visceral fat enlargement that occurs in tandem
with subcutaneous fat loss in lipodystrophies and aging or sub-
cutaneous fat dysfunction in obesity. Reimplantation of healthy
subcutaneous fat reverses these effects (Ishikawa et al., 2006).
Transplantation of inguinal fat into other subcutaneous regions,
or into the abdominal cavity especially, improves the metabolic
profile, whereas transplanting epididymal fat does not (Tran
et al., 2008). The beneficial effects of subcutaneous transplanta-
tion do not depend on adiponectin. These findings are consistent
with the hypothesis that subcutaneous fat dysfunction is more
important than omental fat in the etiology of metabolic syn-
drome, a hypothesis that merits further testing.
In obesity, visceral fat generally enlarges through increases in
fat cell size, whereas subcutaneous fat can enlarge through
increases in fat cell size or number (Figure 3; DiGirolamo et al.,
1998; Tchoukalova et al., 2010), which is perhaps related to
the greater capacities of subcutaneous preadipocytes for repli-
cation and adipogenesis compared to those of visceral cells
from the same subjects. Subcutaneous fat is not uniform:
femoral subcutaneous fat undergoes increases in fat cell
numbers within a few weeks during overfeeding, whereas
abdominal subcutaneous fat does not (Tchoukalova et al.,
2010). Furthermore, loss of leg fat during negative-energy bal-
ance appears to be proportionately lesser than that of other de-
pots, andwhereas leg-fat gain results in the accumulation of new
fat cells, leg-fat loss does not result in the loss of those new cells,
at least over the short term (Singh et al., 2012). In line with this,
femoral fat is more metabolically protective than abdominal sub-
cutaneous fat (Koster et al., 2010). Together with the much
greater mass of subcutaneous compared to visceral fat, the
high capacity for certain subcutaneous regions to generate
new fat cells may prevent visceral fat enlargement and systemic
lipotoxicity (Tchkonia et al., 2006a).Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc. 651
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Central fat is associated with elevated risk for diabetes, hyper-
tension, atherosclerosis, dyslipidemia, and cancers (reviewed
in Shuster et al., 2012) Whether intra-abdominal fat is a cause
or consequence of metabolic dysfunction is controversial.
Nutrient overload induces both subcutaneous and visceral fat
enlargement, but visceral depot size increases rapidly and then
plateaus, whereas subcutaneous fat increases steadily as
obesity develops (Bergman et al., 2006). In normal-weight or
moderately overweight people, visceral obesity is strongly asso-
ciated with insulin resistance, but in severe obesity, it is a weak
independent predictor (Stefan et al., 2008). A pilot study sug-
gested that omentectomy might improve metabolic function in
those undergoing the bariatric surgery procedure of laparo-
scopic banding (Tho¨rne et al., 2002). Subsequent studies have
failed to confirm that removal of omental fat from obese, diabetic
humans improved glucose tolerance after 4 months or provided
added benefit to patients undergoing bariatric surgery (Fabbrini
et al., 2010; Herrera et al., 2010). However, removal of small
amounts of omental fat from healthy, nonobese dogs might
improve insulin sensitivity (Lottati et al., 2009). Removal of
intra-abdominal fat from young rats increased lifespan and pre-
vented age-related insulin resistance (Ben-Shlomo et al., 2012;
Muzumdar et al., 2008). Removing subcutaneous fat from ham-
sters had the opposite effect (Weber et al., 2000).
The lack of a clear benefit from removing omental fat from
obese, metabolically compromised humans despite pro-
nounced effects of removing intra-abdominal fat from rodents
could be due to species differences. Also, intra-abdominal fat
may need to be removed before rather than after the develop-
ment of obesity or metabolic dysfunction to have beneficial
effects. The association between metabolic dysfunction and
visceral obesity could be due to underlying processes that pre-
dispose to both visceral obesity and metabolic dysfunction,
rather than constituting a direct causal relationship (Fabbrini
et al., 2010). Alternatively, inherent differences among fat depots
in fat cell lineage characteristics, such as cytokine secretory pro-
files, may be responsible (Heilbronn et al., 2004).
Conclusions
Fat is not homogeneous. Depot-dependent differences among
preadipocytes, from which new fat cells arise, appear to be
inherent. Regional differences are apparent in rats, mice, and
humans, indicating evolutionary conservation. Given that multi-
ple cell-dynamic processes and developmental gene expression
vary among depots, it appears preadipocytes from different
depots are effectively distinct cell subtypes. These inherent
mechanisms, combined with local variation in fat-depot cellular
composition, circulation, and neurological and other factors,
probably account for regional differences in fat-tissue size and
function. Sex, obesity, or other factors also have fat-depot-
dependent effects on cellular composition, the paracrine micro-
environment, and adipose function. Thus, different fat depots are
separate miniorgans.
Further research is needed for defining the mechanisms
responsible for regional differences in fat-tissue function, deter-
mining whether and how regional differences cause systemic
dysfunction and disease, and developing mechanism-based
interventions accordingly. Immediate questions include whether652 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.visceral obesity is amanifestation of a general process that leads
to systemic metabolic dysfunction, whether it is causal, or
whether subcutaneous fat dysfunction initiates both visceral
obesity and metabolic disease. Evidence is mounting in favor
of the latter, but this requires more investigation. Furthermore,
the roles of particular visceral and subcutaneous depots need
to be determined (e.g., mesenteric versus omental and femoral
versus abdominal subcutaneous).
Some currently available interventions target specific fat
depots. Liposuction and cosmetic surgery can be used to
reduce areas of subcutaneous fat but induce increased visceral
fat (Mauer et al., 2001). It may be feasible to develop antiobesity
drugs with region-specific effects, given that existing agents can
do so, including TZDs, sex steroids, and glucocorticoids
(reviewed in Thomou et al., 2010). Risks associated with central
obesity might be reduced if pharmacological or transplantation
approaches could be developed that would restore the function
of abnormal subcutaneous fat, convert visceral fat depots into
fat with properties more closely resembling those of healthy
subcutaneous depots, or, if intra-abdominal depots (e.g.,
mesenteric fat) do indeed prove to be causally linked to meta-
bolic syndrome, to target these depots. To aid in the rational
development of such interventions, we must understand the
mechanisms responsible for regional obesity and its link tometa-
bolic dysfunction in greater depth.
Subcutaneous fat tissue dysfunction, with failed adipogene-
sis, decreased lipid-storage capacity, and inflammation, could
lead to ectopic fat deposition, with expansion of visceral fat as
an indicator rather than the cause of lipotoxicity. Therefore,
enhancing subcutaneous fat tissue function is potentially a better
approach for treating metabolic syndrome than eliminating
visceral fat. Indeed, TZDs may work this way. If further experi-
mental results indicate that this speculation has merit, screening
for compounds that enhance subcutaneous preadipocyte repli-
cation and adipogenesis might lead to effective treatments for
preventing complications of metabolic syndrome.SUPPLEMENTAL INFORMATION
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